Form 4: Lynx1 Capital Management LP Increases Stake in Passage BIO, Inc.

Lynx1 Capital Management LP reports purchasing 373,645 shares of Passage BIO, Inc. at a weighted average price of $0.6451 per share.

Summary

• On December 27, 2024, Lynx1 Capital Management LP acquired 373,645 shares of Passage BIO, Inc. common stock.
• The shares were purchased at a weighted average price of $0.6451.
• Following the transaction, Lynx1 Capital Management LP beneficially owns 9,256,953 shares indirectly through Lynx1 Master Fund LP.
• Weston Nichols, as the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager, disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a routine transaction of share acquisition by an investment firm. The increase in stake could be interpreted as a positive signal, but without further context, it's difficult to gauge the overall sentiment.

Positives

• Lynx1 Capital Management LP increased its investment in Passage BIO, Inc., signaling potential confidence in the company's future prospects.

Industry Context

This filing reflects investment activity in the biotechnology sector, where investment firms often adjust their holdings based on company performance, clinical trial results, and market conditions.

Stakeholder Impact

• The increased stake by Lynx1 Capital Management LP could positively influence shareholder confidence.

Key Dates